Editing cells in place: Targeted in vivo gene editing of hematopoietic stem cells.

Antibody-engineered lipid nanoparticles achieve efficient and durable in vivo editing of hematopoietic stem cells in humanized mice, advancing gene therapy for blood diseases.

• Why it matters: This work addresses the manufacturing challenges of traditional ex vivo HSC gene therapy and explores a potentially more practical in vivo approach for treating genetic blood disorders.
• What they did: The study used antibody-engineered lipid nanoparticles to target and edit HSCs directly within living organisms, demonstrating successful in vivo gene editing in a humanized mouse model.
• The result: The findings suggest that this nanoparticle-based method could enable a more efficient and durable therapeutic strategy for genetic blood diseases, reducing reliance on ex vivo cell manipulation.